, 95.6% of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemias in the UK were due to two epidemic strains, namely EMRSA-15 or respectively). We sought to determine the proportions of these strains before and after the general decline in MRSA bacteraemia that began around 2004.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) emerged in 1961 and became dramatically more prevalent as agents of bacteraemia in the UK in the mid-1990s in England, Wales and Northern Ireland. By the end of the 1990s, .40% of all S. aureus bacteraemias were due to MRSA, though this proportion (and the total number) of MRSA bacteraemias has since declined and stood at 20% in 2008. 1 The rise of MRSA in the 1990s and early 2000s correlated with the emergence and spread of two epidemic strains, designated EMRSA-15 and EMRSA-16, which, in 1999 -2000, accounted for 95.6% of all UK MRSA bacteraemias; with 60.2% due to EMRSA-15 and 35.4% to EMRSA-16. 2 EMRSA-15 and EMRSA-16 differ genetically, belonging to distinct multilocus sequence type (MLST) clonal complexes (CCs), namely CC22 (ST22) for EMRSA-15 and CC30 (ST36) for EMRSA-16. 3 They also differ in their staphylococcal cassette chromosome mec (SCCmec) types, with EMRSA-15 typically harbouring SCCmecIV whereas EMRSA-16 typically has SCCmecII. 4 They may differ in resistance profile too, but both lineages are usually resistant to fluoroquinolones and macrolides, and the use of these antibiotics has been described as a risk factor for colonization or infection. 5 Since its first emergence in the UK, EMRSA-15 has become disseminated in Europe, 6 Australia, 7 
Materials and methods

Bacterial isolates and collecting centres
The methods for the BSAC Bacteraemia Surveillance Programme (http:// www.bsacsurv.org) have been described previously. 10 In 
Susceptibility testing
MICs were determined on Iso-Sensitest agar (Oxoid, Basingstoke, UK), according to the BSAC method. 3 The antimicrobial agents tested were obtained as described previously. 10 
Molecular detection of CC and SCCmec cassette type
Previously described PCRs were used to detect the SCCmec type 11, 12 and the S. aureus CC-specific marker hsdR, 11 thus differentiating CC22-MRSA-SCCmecIV (corresponding to EMRSA-15) and CC30-MRSA-SCCmecII (corresponding to EMRSA-16).
Data analysis
Regression analysis using the generalized linear model with Poisson distribution was performed via STATA version 10.1 (Statacorp, 2008). As noted previously, the majority of both EMRSA-15 and EMRSA-16 isolates were resistant to macrolides (74% and 85%, respectively) and fluoroquinolones (97% and 95%, respectively), whilst gentamicin resistance was noted in 3% and 24%, respectively. Resistance to tetracyclines was rarer (3% in both strains). Susceptibility to mupirocin was determined only from 2007. Among subsequent isolates, we found 1/8 (13%) EMRSA-16 and 2/76 (3%) EMRSA-15 to be highly resistant (MICs.256 mg/L).
Results and discussion
In summary, the trends observed here suggest that EMRSA-15 and EMRSA-16 have followed different epidemic curves, with EMRSA-16 having peaked and declined earlier than EMRSA-15, and with each then contributing differentially to the total MRSA bacteraemia rate, which peaked in 2004 and declined thereafter. Whilst the reason(s) for the selective decline of EMRSA-16 are not known, various factors, and possible combinations, warrant consideration, including antibiotic prescribing patterns, infection control measures and various possible biological drivers, such as bacteriophage epidemics. It remains to be seen whether the downward trajectory of EMRSA-16 will continue and if EMRSA-15 will remain the dominant MRSA lineage associated with invasive disease in hospitals in the UK. 
